KVA12123,Pembrolizumab
kineta bio,Merck
['biomarker']
$ka kineta unveils that new vista biomarker data provides additional compelling rationale supporting vista as a promising new immuno-oncology target for patients with a range of different cancers 
Options trader. Market-news. Nothing posted constitutes as advice. Do your own diligence.